42 results on '"Nante, G."'
Search Results
2. Reasons for and consequences of vitamin K antagonist discontinuation in very elderly patients with non‐valvular atrial fibrillation
- Author
-
Bertozzo, G., Zoppellaro, G., Granziera, S., Marigo, L., Rossi, K., Petruzzellis, F., Perissinotto, E., Manzato, E., Nante, G., and Pengo, V.
- Published
- 2016
- Full Text
- View/download PDF
3. Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study
- Author
-
Riva, N., Ageno, W., Poli, D., Testa, S., Rupoli, S., Santoro, R., Lerede, T., Piana, A., Carpenedo, M., Nicolini, A., Ferrini, P.M., Tosetto, A., Paoletti, O., Rancan, E., Federici, I., Canafoglia, L., Maggioni, A., Falanga, A., Martini, G., Mangione, C., Contino, L., Bonfanti, C., Gresele, P., Pedrini, S., Morandini, R., Marigo, L., Nante, G., Sivera, P., Pasca, S., Malcangi, G., Ettorre, C.P., Cavallero, G.B., Falco, P., Ruocco, L., Paparo, C., Bucherini, E., Suriano, L., Crisantemo, R., Ria, L., Toma, A., Insana, A., Zanatta, N., Zammataro, N., Iannone, A.M., Oriana, V., Pezzo, M.P., Isu, G., and Molinatti, M.
- Published
- 2015
- Full Text
- View/download PDF
4. The incidence of chronic thromboembolic pulmonary hypertension and the predictive value of residual arterial pulmonary obstruction: results from a large, multicentre, prospective cohort study: OR132
- Author
-
Pesavento, R, Filippi, L, Palla, A, Frigo, A, Visonà, A, Bova, C, Cuppini, S, Porro, F, Villalta, S, Ciammaichella, M M, Bucherini, E, Nante, G, Battistelli, S, Beltramello, G, Prisco, D, and Prandoni, P
- Published
- 2015
5. Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases
- Author
-
Denas, G., Marzot, F., Offelli, P., Stendardo, A., Cucchini, U., Russo, R., Nante, G., Iliceto, S., and Pengo, Vittorio
- Published
- 2009
- Full Text
- View/download PDF
6. Vitamin K antagonists (VKA) for stroke prevention in atrial fibrillation (AF) in very elderly naïve patients: PB 1.47–2
- Author
-
Granziera, S, Bertozzo, G, Marigo, L, Petruzzellis, F, Rossi, K, Infante, T, Pletti, S, Nante, G, Manzato, E, and Pengo, V
- Published
- 2013
7. Recurrence of intracranial hemorrhage after resumption of anticoagulation in patients who had a first episode occurred during Vitamin K Antagonists anticoagulation. Results of a collaborative study: OC 42.2
- Author
-
Daniela, P, Antonucci, E, Testa, S, Erba, N, Guazzaloca, G, Tiraferri, E, Ciardiello, A, Lerede, T, Nante, G, and Palareti, G
- Published
- 2013
8. VKORC1, CYP2C9 AND CYP4F2 GENETIC BASED ALGORITHM FOR WARFARIN DOSING. PRELIMINARY RESULTS OF A PROSPECTIVE ITALIAN STUDY
- Author
-
Pelloso, M., Pengo, V., Zambon, C., Fogar, P., Moz, S., Nante, G., Russo, R., Tiso, E., Padrini, R., Nisi, A., Basso, D., and Plebani, M.
- Published
- 2010
9. Cognitive decline in the elderly: A double- blind, placebo- controlled multicenter study on efficacy of phosphatidylserine administration
- Author
-
Cenacchi, Teresa, Bertoldin, T., Farina, C., Fiori, M. G., Crepaldi, G., Azzini, C. F., Girardello, R., Bagozzi, B., Garuti, R., Vivaldi, P., Belloni, G., Bordin, A., Durando, M., Lo Storto, M., Bertoni, L., Battistoni, A., Cacace, C., Arduini, P., Bonini, A., Caramia, M. P., Vaglieri, G., Brusomini, A., Donà, G., March, A., Campi, N., Cannas, P., Casson, F., Cavallarin, G., Delia, M., Cristianini, G., Louvier, O., Mello, F., Fameli, R., Urbani de Gheltoff, N., De Candia, O., Nante, G., Cattoni, C., Forte, P. L., Loreggian, M., Targa, A., Mansoldo, G., Noro, G., Meggio, A., Pedrazzi, F., Bonmartini, F., Ruggiano, C., Peruzza, M., Olivari, G., Recaldin, E., Bellunato, C., Rigo, G., Marin, M., Marinangeli, L., Saracino, A., Miceli, O., Lovo, G., Scarpa, R., Battistello, L., Tomat, E., Bernava, B., Olivo, P., Verga, G., Merli, G., Zerman, A. M., Crivellaro, R., Vozza, A., Ziliotto, G. R., Favaretto, V., and Allegro, L.
- Published
- 1993
- Full Text
- View/download PDF
10. P1564Atrial fibrillation and thromboembolic prophylaxis: focus on the frail oldest patient. how net clinical benefit influences anticoagulant therapy
- Author
-
Greco, G I, primary, Ninivaggi, C, additional, Graceffa, A, additional, Novello, S, additional, Bonfante, F, additional, Di Stasio, F, additional, Zambotti, E, additional, Tavian, T, additional, Zorzi, A, additional, Sartori, M, additional, Occhipinti, G, additional, Granziera, S, additional, Nante, G, additional, Sergi, G, additional, and Manzato, E, additional
- Published
- 2019
- Full Text
- View/download PDF
11. P6258Direct oral anticoagulants in non-valvular atrial fibrillation: accuracy of traditional bleeding scores in the elderly
- Author
-
Novello, S, primary, Graceffa, A, additional, Ninivaggi, C, additional, Greco, G I, additional, Bonfante, F, additional, Di Stasio, F, additional, Zambotti, E, additional, Zorzi, A, additional, Tavian, T, additional, Sartori, M, additional, Occhipinti, G, additional, Granziera, S, additional, Nante, G, additional, Sergi, G, additional, and Manzato, E, additional
- Published
- 2019
- Full Text
- View/download PDF
12. Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry
- Author
-
Pastori, D, Antonucci, E, Violi, F, Palareti, G, Pignatelli, P, Testa, S, Paoletti, O, Cosmi, B, Guazzaloca, G, Migliaccio, L, Poli, D, Marcucci, R, Maggini, N, Pengo, V, Falanga, A, Lerede, T, Ruocco, L, Martini, G, Pedrini, S, Bertola, F, Masciocco, L, Saracino, P, Benvenuto, A, Vasselli, C, Grandone, E, Colaizzo, D, Marzolo, M, Pinelli, M, Mastroiacovo, D, Ageno, W, Colombo, G, Bucherini, E, Serra, D, Toma, A, Barbera, P, Paparo, C, Insana, A, Rupoli, S, Malcangi, G, Zighetti, M, Mangione, C, Lione, D, Casasco, P, Nante, G, Tosetto, A, Oriana, V, Liberato, N, Zighetti, ML, Liberato, NL, Pastori, D, Antonucci, E, Violi, F, Palareti, G, Pignatelli, P, Testa, S, Paoletti, O, Cosmi, B, Guazzaloca, G, Migliaccio, L, Poli, D, Marcucci, R, Maggini, N, Pengo, V, Falanga, A, Lerede, T, Ruocco, L, Martini, G, Pedrini, S, Bertola, F, Masciocco, L, Saracino, P, Benvenuto, A, Vasselli, C, Grandone, E, Colaizzo, D, Marzolo, M, Pinelli, M, Mastroiacovo, D, Ageno, W, Colombo, G, Bucherini, E, Serra, D, Toma, A, Barbera, P, Paparo, C, Insana, A, Rupoli, S, Malcangi, G, Zighetti, M, Mangione, C, Lione, D, Casasco, P, Nante, G, Tosetto, A, Oriana, V, Liberato, N, Zighetti, ML, and Liberato, NL
- Abstract
Background Thrombocytopenia is associated with increased mortality in the general population, but few data exist in patients with atrial fibrillation (AF) taking oral anticoagulants. We investigated factor determinants of thrombocytopenia in a large cohort of patients affected by AF and its association with total mortality. Methods and Results Multicenter prospective cohort study, including 5215 patients with AF from the START (Survey on Anticoagulated Patients Register) registry, 3877 (74.3%) and 1338 (25.7%) on vitamin K or non-vitamin K antagonist oral anticoagulants, respectively. Thrombocytopenia was defined by a platelet count <150×109/L. Determinants of thrombocytopenia were investigated, and all-cause mortality was the primary survival end point of the study. Thrombocytopenia was present in 592 patients (11.4%). At multivariable logistic regression analysis, chronic kidney disease (odds ratio [OR], 1.257; P=0.030), active cancer (OR, 2.065; P=0.001), liver cirrhosis (OR, 7.635; P<0.001), and the use of diuretics (OR, 1.234; P=0.046) were positively associated with thrombocytopenia, whereas female sex (OR, 0.387; P<0.001) and the use of calcium channel blockers (OR, 0.787; P=0.032) were negatively associated. During a median follow-up of 19.2 months (9942 patient-years), 391 deaths occurred (rate, 3.93%/year). Mortality rate increased from 3.8%/year to 9.9%/year in patients with normal platelet count and in those with moderate-severe thrombocytopenia, respectively (log-rank test, P=0.009). The association between moderate-severe thrombocytopenia and mortality persisted after adjustment for CHA2DS2 VASc score (hazard ratio, 2.431; 95% CI, 1.254-4.713; P=0.009), but not in the fully adjusted multivariable Cox regression analysis model. Conclusions Thrombocytopenia is common in patients with AF. Despite an increased incidence of mortality, thrombocytopenia was not associated with mortality at multivariable analysis. Thrombocytopenia may reflect the pres
- Published
- 2019
13. Prescription of vitamin K inhibitors in low-risk patients with atrial fibrillation
- Author
-
Granziera, S., Nante, G., Manzato, E., and Pengo, V.
- Published
- 2011
- Full Text
- View/download PDF
14. Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study
- Author
-
Riva, N, Ageno, W, Poli, D, Testa, S, Rupoli, S, Santoro, R, Lerede, T, Piana, A, Carpenedo, M, Nicolini, A, Ferrini, P, Tosetto, A, Paoletti, O, Rancan, E, Federici, I, Canafoglia, L, Lancisi, G, Salesi, G, Maggioni, A, Falanga, A, Martini, G, Mangione, C, Contino, L, Bonfanti, C, Gresele, P, Marigo, L, Nante, G, Sivera, P, Pasca, S, Malcangi, G, Ettorre, C, Cavallero, B, Falco, P, Ruocco, L, Paparo, C, Bucherini, E, Suriano, L, Crisantemo, R, Toma, A, Insana, A, Zanatta, N, Iannone, A, Oriana, V, Pezzo, M, Isu, G, Molinatti, M, Riva N, Ageno W, Poli D, Testa S, Rupoli S, Santoro R, Lerede T, Piana A, Carpenedo M, Nicolini A, Ferrini PM, Tosetto A, Paoletti O, Rancan E, Federici I, Canafoglia L, Lancisi GM, Salesi G, Maggioni A, Falanga A, Martini G, Mangione C, Contino L, Bonfanti C, Gresele P, Marigo L, Nante G, Sivera P, Pasca S, Malcangi G, Ettorre CP, Cavallero B, Falco P, Ruocco L, Paparo C, Bucherini E, Suriano L, Crisantemo R, Toma A, Insana A, Zanatta N, Iannone AM, Oriana V, Pezzo MP, Isu G, Molinatti M, Riva, N, Ageno, W, Poli, D, Testa, S, Rupoli, S, Santoro, R, Lerede, T, Piana, A, Carpenedo, M, Nicolini, A, Ferrini, P, Tosetto, A, Paoletti, O, Rancan, E, Federici, I, Canafoglia, L, Lancisi, G, Salesi, G, Maggioni, A, Falanga, A, Martini, G, Mangione, C, Contino, L, Bonfanti, C, Gresele, P, Marigo, L, Nante, G, Sivera, P, Pasca, S, Malcangi, G, Ettorre, C, Cavallero, B, Falco, P, Ruocco, L, Paparo, C, Bucherini, E, Suriano, L, Crisantemo, R, Toma, A, Insana, A, Zanatta, N, Iannone, A, Oriana, V, Pezzo, M, Isu, G, Molinatti, M, Riva N, Ageno W, Poli D, Testa S, Rupoli S, Santoro R, Lerede T, Piana A, Carpenedo M, Nicolini A, Ferrini PM, Tosetto A, Paoletti O, Rancan E, Federici I, Canafoglia L, Lancisi GM, Salesi G, Maggioni A, Falanga A, Martini G, Mangione C, Contino L, Bonfanti C, Gresele P, Marigo L, Nante G, Sivera P, Pasca S, Malcangi G, Ettorre CP, Cavallero B, Falco P, Ruocco L, Paparo C, Bucherini E, Suriano L, Crisantemo R, Toma A, Insana A, Zanatta N, Iannone AM, Oriana V, Pezzo MP, Isu G, and Molinatti M
- Abstract
Background: The treatment of splanchnic vein thrombosis (SVT) is challenging, due to the increased risk of bleeding and potentially life-threatening complications. Current recommendations are based on evidence from the treatment of venous thrombosis in usual sites, but small observational studies in SVT population suggest that the bleeding risk may offset the benefit of anticoagulant treatment in this setting. The aim of this study was to evaluate the safety of vitamin K antagonists (VKAs) in SVT patients. Methods: We retrospectively included SVT patients treated with VKAs followed by 37 Italian anticoagulation clinics, until June 2013. The primary outcome was the incidence of major bleeding (MB), according to the ISTH definition, during VKA treatment. Vascular events, including both arterial and venous thrombosis, and mortality were also documented. Results: Three hundred and seventy-five patients were included (median age 53 years; 54.7% males). During a median VKA treatment duration of 1.98 years, 15 MB events occurred, corresponding to an incidence rate of 1.24 (95% confidence interval [CI], 0.75-2.06) per 100 patient-years. Gastrointestinal bleeding represented 40% of all MB events. At multivariate analysis, the presence of esophageal varices emerged as independent predictor of MB (hazard ratio 5.4; 95% CI, 1.4-21.1). The incidence rate of vascular events on treatment was 1.37 (95% CI, 0.84-2.23) per 100 patient-years and the mortality rate was 0.83 (95% CI, 0.44-1.54) per 100 patient-years. Conclusions: Selected SVT patients followed by anticoagulation clinics for the management of VKA treatment show a low rate of major bleeding and vascular events.
- Published
- 2015
15. Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism
- Author
-
Pesavento, R, Filippi, L, Palla, A, Visonà, A, Bova, C, Marzolo, M, Porro, F, Villalta, S, Ciammaichella, M, Bucherini, E, Nante, G, Battistelli, S, Muiesan, Ml, Beltramello, G, Prisco, D, Casazza, F, Ageno, W, Palareti, G, Quintavalla, R, Monti, S, Mumoli, N, Zanatta, N, Cappelli, R, Cattaneo, M, Moretti, V, Corà, F, Bazzan, M, Ghirarduzzi, A, Frigo, Ac, Miniati, M, Prandoni, P, and Scope, Investigators
- Published
- 2017
16. Bleeding Risk in Very Old Patients on Vitamin K Antagonist Treatment
- Author
-
Polimanti, David, Antonucci, Eva, Testa, S., Tosetto, A., Ageno, W., Palareti, G., Collaborators: Poli, Italian Federation Of Anticoagulation C. l. i. n. i. c. s., Paoletti, O., Nante, G., Pengo, V., Carini, U., Guazzaloca, G., Scortechini, A. R., Canafoglia, L., Tomassetti, S., Restifo, D., Ciampa, A., Pignatelli, Pasquale, Basili, Stefania, Saliola, M., Di Gennaro, L., De Cristofaro, R., Caprioli, M., Pedrini, S., Orlandini, F., Benedetti, R., Ruocco, L., Tiraferri, E., Cappelli, R., Piana, A., Armani, U., Porcu, A., Falco, P., Da Col, P., Marongiu, F., Barcellona, D., Falanga, A., Lerede, T., Galbo, L., Bucherini, E., Insana, A., Grasso, M. V., Masciocco, L., and Pini, F.
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Vitamin K ,medicine.drug_class ,venous thromboembolism ,Hemorrhage ,elderly ,atrial fibrillation ,hemorrhage ,warfarin ,Age Distribution ,Aged, 80 and over ,Anticoagulants ,Atrial Fibrillation ,Cooperative Behavior ,Female ,Humans ,Incidence ,Italy ,Proportional Hazards Models ,Prospective Studies ,Risk Factors ,Stroke ,Venous Thromboembolism ,Physiology (medical) ,Cardiology and Cardiovascular Medicine ,oral anticoagulation ,80 and over ,medicine ,Medical prescription ,Prospective cohort study ,Aged ,Proportional hazards model ,business.industry ,Incidence (epidemiology) ,Warfarin ,Atrial fibrillation ,Vitamin K antagonist ,medicine.disease ,Surgery ,business ,medicine.drug - Abstract
Background— Vitamin K antagonist (VKA) therapy is increasingly being used for the prevention of venous thromboembolism and stroke in atrial fibrillation. Bleeds are the major concern for VKA prescription, especially in very old patients who carry many risk factors for bleeding. We performed a large multicenter prospective observational study that enrolled very old patients to evaluate the quality of anticoagulation and the incidence of bleedings. Methods and Results— The study included 4093 patients ≥80 years of age who were naïve to VKA for thromboprophylaxis of atrial fibrillation or after venous thromboembolism. Patients' demographic and clinical data were collected, and the quality of anticoagulation and the incidence of bleeding were recorded. The follow-up was 9603 patient-years; median age at the beginning of follow-up was 84 years (range, 80 to 102 years). We recorded 179 major bleedings (rate, 1.87 per 100 patient-years), 26 fatal (rate, 0.27 per 100 patient-years). The rate of bleeding was higher in men compared with women (relative risk, 1.4; 95% confidence interval, 1.12 to 1.72; P =0.002) and among patients ≥85 years of age compared with younger patients (relative risk, 1.3; 95% confidence interval, 1.0 to 1.65; P =0.048). Time in therapeutic range was 62% (interquartile range, 49% to 75%). History of bleeding, active cancer, and history of falls were independently associated with bleeding risk in Cox regression analysis. Conclusion— In this large study on very old patients on VKA carefully monitored by anticoagulation clinics, the rate of bleedings was low, suggesting that age in itself should not be considered a contraindication to treatment. Adequate management of VKA therapy in specifically trained center allows very old and frail patients to benefit from VKA thromboprophylaxis.
- Published
- 2011
- Full Text
- View/download PDF
17. The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study
- Author
-
Poli, D., Antonucci, E., Testa, S., Cosmi, B., Palareti, G., Ageno, W., Italian Federation Of Anticoagulation Clinics Poli, Fcsa D., Paoletti, O., Nante, G., Pengo, V., Carini, U., Guazzaloca, G., Scortechini, A. R., Canafoglia, L., Tomassetti, S., Restifo, D., Desio Vimercate, A. O., Ciampa, A., Pignatelli, Pasquale, Basili, Stefania, Saliola, Mirella, Di Gennaro, L., De Cristofaro, R., Caprioli, M., Pedrini, S., Orlandini, F., Benedetti, R., Ruocco, L., Tiraferri, E., Cappelli, R., Piana, A., Armani, U., Porcu, A., Falco, P., Da Col, P., Marongiu, F., Barcellona, D., Falanga, A., Lerede, T., Galbo, L., Bucherini, E., Insana, A., Masciocco, L., Pini, F., D. Poli, E. Antonucci, S. Testa, B. Cosmi, G. Palareti, W. Ageno, Poli, D, Antonucci, E, Testa, S, Cosmi, B, Palareti, G, Ageno, W, Paoletti, O, Nante, G, Pengo, V, Carini, U, Guazzaloca, G, Scortechini, A, Canafoglia, L, Tomassetti, S, Restifo, D, Ciampa, A, Pignatelli, P, Basili, S, Saliola, M, Di Gennaro, L, De Cristofaro, R, Caprioli, M, Pedrini, S, Orlandini, F, Benedetti, R, Ruocco, L, Tiraferri, E, Cappelli, R, Piana, A, Armani, U, Porcu, A, Falco, P, Dal Col, P, Marongiu, F, Barcellona, D, Falanga, A, Lerede, T, Galbo, L, Bucherini, E, Insana, A, Masciocco, L, and Pini, F
- Subjects
bleeding, bleeding scores, elderly venous thromboembolism, vitamin K, antagonist ,Predictive validity ,Bleeding ,Bleeding scores ,Elderly ,Venous thromboembolism ,Vitamin K antagonist ,medicine.medical_specialty ,vitamin K antagonist ,medicine.drug_class ,Internal medicine ,Atrial Fibrillation ,Medicine ,Prospective cohort study ,Old patients ,business.industry ,Proportional hazards model ,Risk Factor ,Mortality rate ,Hematology ,Surgery ,bleeding score ,bleeding ,bleeding scores ,elderly ,venous thromboembolism ,vitamin k antagonist ,Risk stratification ,business - Abstract
BACKGROUND: The optimal duration of anticoagulant treatment after venous thromboembolism (VTE) should be evaluated in relation to bleeding risk. This assessment is particularly difficult with elderly patients, because of their increased risk of both recurrences and hemorrhages. Bleeding risk stratification models have been proposed, but their predictive ability in very elderly patients is unknown. We aimed to assess six bleeding stratification models in this setting, by using information available in our dataset. PATIENTS AND METHODS: Patients aged >/= 80 years receiving vitamin K antagonists (VKAs) for the secondary prevention of VTE were eligible for this prospective cohort study. All patients were followed at Italian anticoagulation clinics for monitoring of VKA treatment. Risk factors for bleeding were collected, and major bleeding events and mortality were documented during follow-up. The association of bleeding events with the available risk factors was tested by means of Cox regression analysis; the c-statistic was used to quantify the predictive validity of the classification schemes. RESULTS: A total of 1078 patients (37.2% males; mean age, 84 years) were enrolled in the study, for a total observation period of 1981 patient-years. The rate of major bleeding was 2.4 per 100 patient-years (47 events; one was fatal). The mortality rate was 5.2 per 100 patient-years. None of the considered risk factors were significantly associated with bleeding events. The predictive validity of the risk stratification models was low, and the most accurate model was not specifically developed for VTE patients (HEMORR2 HAGES, c-statistic 0.60, 95% confidence interval 0.49-0.70). CONCLUSIONS: Bleeding risk stratification models appear to have little accuracy in very elderly VTE patients.
- Published
- 2013
18. Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism
- Author
-
Pengo, Vittorio, Lensing, A. W. A., Prins, M. H., Marchiori, A., Davidson, B. L., Tiozzo, F., Albanese, P., Biasiolo, A., Pegoraro, C., Iliceto, Sabino, Prandoni, Paolo, Razzolini, Renato, Ramondo, A., Bellotto, F., Noventa, Franco, Villanova, C., Barbero, F., Casara, F., Nante, G., Tormene, Daniela, Gerosa, Gino, Testolin, L., Bottio, Tomaso, Piovella, F., Vigano', M., and D'Armini, A.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Hypertension, Pulmonary ,medicine.medical_treatment ,Recurrence ,Risk Factors ,Thromboembolism ,Internal medicine ,medicine ,Pulmonary angiography ,Humans ,Cumulative incidence ,Pulmonary wedge pressure ,Aged ,Pulmonary thromboendarterectomy ,business.industry ,Incidence ,Respiratory disease ,Age Factors ,General Medicine ,Odds ratio ,Middle Aged ,medicine.disease ,Pulmonary hypertension ,Surgery ,Pulmonary embolism ,Logistic Models ,Chronic Disease ,Cardiology ,Female ,Pulmonary Embolism ,business ,Follow-Up Studies - Abstract
background Chronic thromboembolic pulmonary hypertension (CTPH) is associated with considerable morbidity and mortality. Its incidence after pulmonary embolism and associated risk factors are not well documented. methods We conducted a prospective, long-term, follow-up study to assess the incidence of symptomatic CTPH in consecutive patients with an acute episode of pulmonary embolism but without prior venous thromboembolism. Patients with unexplained persistent dyspnea during follow-up underwent transthoracic echocardiography and, if supportive findings were present, ventilation–perfusion lung scanning and pulmonary angiography. CTPH was considered to be present if systolic and mean pulmonary-artery pressures exceeded 40 mm Hg and 25 mm Hg, respectively; pulmonary-capillary wedge pressure was normal; and there was angiographic evidence of disease. results The cumulative incidence of symptomatic CTPH was 1.0 percent (95 percent confidence interval, 0.0 to 2.4) at six months, 3.1 percent (95 percent confidence interval, 0.7 to 5.5) at one year, and 3.8 percent (95 percent confidence interval, 1.1 to 6.5) at two years. No cases occurred after two years among the patients with more than two years of follow-up data. The following increased the risk of CTPH: a previous pulmonary embolism (odds ratio, 19.0), younger age (odds ratio, 1.79 per decade), a larger perfusion defect (odds ratio, 2.22 per decile decrement in perfusion), and idiopathic pulmonary embolism at presentation (odds ratio, 5.70). conclusions CTPH is a relatively common, serious complication of pulmonary embolism. Diagnostic and therapeutic strategies for the early identification and prevention of CTPH are needed.
- Published
- 2004
- Full Text
- View/download PDF
19. Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study
- Author
-
Pengo, V, Cucchini, U, Denas, G, Erba, N, Guazzaloca, G, La Rosa, L, De Micheli, V, Testa, S, Frontoni, R, Prisco, D, Nante, G, Iliceto, S, Moia, M, Oliviero, B, Molinatti, M, Cappelli, R, Zasso, A, Carrer, A, Borella, C, Ciabatta, C, Poli, D, Pollio, G, Iannone, AM, Coffetti, N, Pagliaro, P, Pedico, P, Porcu, A, Lorenz, C., SIRAGUSA, Sergio, Pengo, V, Cucchini, U, Denas, G, Erba, N, Guazzaloca, G, La Rosa, L, De Micheli, V, Testa, S, Frontoni, R, Prisco, D, Nante, G, Iliceto, S, Moia, M, Oliviero, B, Molinatti, M, Cappelli, R, Zasso, A, Carrer, A, Borella, C, Siragusa, S, Ciabatta, C, Poli, D, Pollio, G, Iannone, AM, Coffetti, N, Pagliaro, P, Pedico, P, Porcu, A, and Lorenz, C
- Subjects
Bridging, low molecular wight heparins ,Settore MED/15 - Malattie Del Sangue - Abstract
BACKGROUND: Bridging therapy with low-molecular-weight heparin is usually recommended in patients who must stop oral anticoagulants before surgical or invasive procedures. To date, there is no universally accepted bridging regimen tailored to the patient's thromboembolic risk. This prospective inception cohort management study was designed to assess the efficacy and safety of an individualized bridging protocol applied to outpatients. METHODS AND RESULTS: Oral anticoagulants were stopped 5 days before the procedure. Low-molecular-weight heparin was started 3 to 4 days before surgery and continued for 6 days after surgery at 70 anti-factor Xa U/kg twice daily in high-thromboembolic-risk patients and prophylactic once-daily doses in moderate- to low-risk patients. Oral anticoagulation was resumed the day after the procedure with a boost dose of 50% for 2 days and maintenance doses afterward. The patients were followed up for 30 days. Of the 1262 patients included in the study (only 15% had mechanical valves), 295 (23.4%) were high-thromboembolic-risk patients and 967 (76.6%) were moderate- to low-risk patients. In the intention-to-treat analysis, there were 5 thromboembolic events (0.4%; 95% confidence interval, 0.1 to 0.9), all in high-thromboembolic-risk patients. There were 15 major (1.2%; 95% confidence interval, 0.7 to 2.0) and 53 minor (4.2%; 95% confidence interval, 3.2 to 5.5) bleeding episodes. Major bleeding was associated with twice-daily low-molecular-weight heparin administration (high-risk patients) but not with the bleeding risk of the procedure. CONCLUSIONS: This management bridging protocol, tailored to patients' thromboembolic risk, appears to be feasible, effective, and safe for many patients, but safety in patients with mechanical prosthetic valves has not been conclusively established.
- Published
- 2009
20. VKORC1, CYP2C9 AND CYP4F2 GENETIC BASED ALGORITHM FOR WARFARIN DOSING: PRELIMINARY RESULTS OF A PROSPECTIVE ITALIAN STUDY
- Author
-
Pelloso, Michela, Zambon, CARLO-FEDERICO, Pengo, Vittorio, Fogar, P., Moz, Stefania, Gnatta, Elisa, Tessari, Alberto, Groppa, F., Nante, G., Tiso, E., Padrini, Roberto, Basso, Daniela, and Plebani, Mario
- Published
- 2012
21. A multicenter study on heart arrhythmia in facioscapulohumeral muscular dystrophy
- Author
-
Trevisan, C. P., Rigoni, M. T., Tonello, S., Armani, M., Pastorello, E., Angelini, Corrado, Tomelleri, G., Tonin, P., Mongini, T., Bosone, I., Siciliano, G., Sposito, R., and Nante, G.
- Published
- 2002
22. The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study
- Author
-
Poli, D, Antonucci, E, Testa, S, Cosmi, B, Palareti, G, Ageno, W, Paoletti, O, Nante, G, Pengo, V, Carini, U, Guazzaloca, G, Scortechini, A, Canafoglia, L, Tomassetti, S, Restifo, D, Ciampa, A, Pignatelli, P, Basili, S, Saliola, M, Di Gennaro, L, De Cristofaro, R, Caprioli, M, Pedrini, S, Orlandini, F, Benedetti, R, Ruocco, L, Tiraferri, E, Cappelli, R, Piana, A, Armani, U, Porcu, A, Falco, P, Dal Col, P, Marongiu, F, Barcellona, D, Falanga, A, Lerede, T, Galbo, L, Bucherini, E, Insana, A, Masciocco, L, Pini, F, Scortechini, AR, Poli, D, Antonucci, E, Testa, S, Cosmi, B, Palareti, G, Ageno, W, Paoletti, O, Nante, G, Pengo, V, Carini, U, Guazzaloca, G, Scortechini, A, Canafoglia, L, Tomassetti, S, Restifo, D, Ciampa, A, Pignatelli, P, Basili, S, Saliola, M, Di Gennaro, L, De Cristofaro, R, Caprioli, M, Pedrini, S, Orlandini, F, Benedetti, R, Ruocco, L, Tiraferri, E, Cappelli, R, Piana, A, Armani, U, Porcu, A, Falco, P, Dal Col, P, Marongiu, F, Barcellona, D, Falanga, A, Lerede, T, Galbo, L, Bucherini, E, Insana, A, Masciocco, L, Pini, F, and Scortechini, AR
- Abstract
Background: The optimal duration of anticoagulant treatment after venous thromboembolism (VTE) should be evaluated in relation to bleeding risk. This assessment is particularly difficult with elderly patients, because of their increased risk of both recurrences and hemorrhages. Bleeding risk stratification models have been proposed, but their predictive ability in very elderly patients is unknown. We aimed to assess six bleeding stratification models in this setting, by using information available in our dataset. Patients and methods: Patients aged ≥ 80 years receiving vitamin K antagonists (VKAs) for the secondary prevention of VTE were eligible for this prospective cohort study. All patients were followed at Italian anticoagulation clinics for monitoring of VKA treatment. Risk factors for bleeding were collected, and major bleeding events and mortality were documented during follow-up. The association of bleeding events with the available risk factors was tested by means of Cox regression analysis; the c-statistic was used to quantify the predictive validity of the classification schemes. Results: A total of 1078 patients (37.2% males; mean age, 84 years) were enrolled in the study, for a total observation period of 1981 patient-years. The rate of major bleeding was 2.4 per 100 patient-years (47 events; one was fatal). The mortality rate was 5.2 per 100 patient-years. None of the considered risk factors were significantly associated with bleeding events. The predictive validity of the risk stratification models was low, and the most accurate model was not specifically developed for VTE patients (HEMORR2HAGES, c-statistic 0.60, 95% confidence interval 0.49-0.70). Conclusions: Bleeding risk stratification models appear to have little accuracy in very elderly VTE patients
- Published
- 2013
23. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation
- Author
-
Pengo, Vittorio, Zasso, A, Barbero, F, Banzato, A, Nante, G, Parissenti, L, John, N, Noventa, Franco, and DALLA VOLTA, S.
- Published
- 1998
24. Causes for vitamin K antagonist discontinuation in elderly patients with atrial fibrillation
- Author
-
Bertozzo, G., primary, Granziera, S., additional, Petruzzellis, F., additional, Marigo, L., additional, Rossi, K., additional, Infante, T., additional, Pletti, S., additional, Nante, G., additional, and Manzato, E., additional
- Published
- 2013
- Full Text
- View/download PDF
25. Prescription of vitamin K inhibitors in low-risk patients with atrial fibrillation
- Author
-
Granziera, S., primary, Nante, G., additional, Manzato, E., additional, and Pengo, V., additional
- Published
- 2010
- Full Text
- View/download PDF
26. Standardized Low–Molecular-Weight Heparin Bridging Regimen in Outpatients on Oral Anticoagulants Undergoing Invasive Procedure or Surgery
- Author
-
Pengo, V., primary, Cucchini, U., additional, Denas, G., additional, Erba, N., additional, Guazzaloca, G., additional, La Rosa, L., additional, De Micheli, V., additional, Testa, S., additional, Frontoni, R., additional, Prisco, D., additional, Nante, G., additional, and Iliceto, S., additional
- Published
- 2009
- Full Text
- View/download PDF
27. Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases
- Author
-
Denas, G., primary, Marzot, F., additional, Offelli, P., additional, Stendardo, A., additional, Cucchini, U., additional, Russo, R., additional, Nante, G., additional, Iliceto, S., additional, and Pengo, Vittorio, additional
- Published
- 2008
- Full Text
- View/download PDF
28. BODY COMPOSITION IN NORMAL-WEIGHT ELDERLY SUBJECTS: PRELIMINARY OBSERVATION
- Author
-
Sergi, G., Baggio, Bruno, Perini, P., Nante, G., Pavan, M., Busetto, Luca, D'Angelo, Angela, and Enzi, G.
- Published
- 1992
29. VKORC1, CYP2C9 AND CYP4F2 GENETIC BASED ALGORITHM FOR WARFARIN DOSING. PRELIMINARY RESULTS OF A PROSPECTIVE ITALIAN STUDY
- Author
-
CARLO-FEDERICO ZAMBON, Pelloso, M., Pengo, V., Fogar, P., Moz, S., Nante, G., Russo, R., Tiso, E., Padrini, R., Nisi, A., Basso, D., and Plebani, M.
30. Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry
- Author
-
Daniele Pastori, Emilia Antonucci, Francesco Violi, Gualtiero Palareti, Pasquale Pignatelli, Sophie Testa, Oriana Paoletti, Benilde Cosmi, Giuliana Guazzaloca, Ludovica Migliaccio, Daniela Poli, Rossella Marcucci, Niccolò Maggini, Vittorio Pengo, Anna Falanga, Teresa Lerede, Lucia Ruocco, Giuliana Martini, Simona Pedrini, Federica Bertola, Lucilla Masciocco, Pasquale Saracino, Angelo Benvenuto, Claudio Vasselli, Elvira Grandone, Donatella Colaizzo, Marco Marzolo, Mauro Pinelli, Walter Ageno, Giovanna Colombo, Eugenio Bucherini, Domizio Serra, Andrea Toma, Pietro Barbera, Carmelo Paparo, Antonio Insana, Serena Rupoli, Giuseppe Malcangi, Maddalena Loredana Zighetti, Catello Mangione, Domenico Lione, Paola Casasco, Giovanni Nante, Alberto Tosetto, Vincenzo Oriana, Nicola Lucio Liberato, Pastori D., Antonucci E., Violi F., Palareti G., Pignatelli P., Testa S., Paoletti O., Cosmi B., Guazzaloca G., Migliaccio L., Poli D., Marcucci R., Maggini N., Pengo V., Falanga A., Lerede T., Ruocco L., Martini G., Pedrini S., Bertola F., Masciocco L., Saracino P., Benvenuto A., Vasselli C., Grandone E., Colaizzo D., Marzolo M., Pinelli M., Ageno W., Colombo G., Bucherini E., Serra D., Toma A., Barbera P., Paparo C., Insana A., Rupoli S., Malcangi G., Zighetti M.L., Mangione C., Lione D., Casasco P., Nante G., Tosetto A., Oriana V., Liberato N.L., Pastori, D, Antonucci, E, Violi, F, Palareti, G, Pignatelli, P, Testa, S, Paoletti, O, Cosmi, B, Guazzaloca, G, Migliaccio, L, Poli, D, Marcucci, R, Maggini, N, Pengo, V, Falanga, A, Lerede, T, Ruocco, L, Martini, G, Pedrini, S, Bertola, F, Masciocco, L, Saracino, P, Benvenuto, A, Vasselli, C, Grandone, E, Colaizzo, D, Marzolo, M, Pinelli, M, Mastroiacovo, D, Ageno, W, Colombo, G, Bucherini, E, Serra, D, Toma, A, Barbera, P, Paparo, C, Insana, A, Rupoli, S, Malcangi, G, Zighetti, M, Mangione, C, Lione, D, Casasco, P, Nante, G, Tosetto, A, Oriana, V, and Liberato, N
- Subjects
Male ,medicine.medical_specialty ,Population ,thrombocytopenia ,Arrhythmias ,030204 cardiovascular system & hematology ,Risk Assessment ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Arrhythmia and Electrophysiology ,In patient ,atrial fibrillation ,Prospective Studies ,Registries ,mortality ,education ,Aged ,Original Research ,education.field_of_study ,business.industry ,Atrial fibrillation ,medicine.disease ,Italy ,030220 oncology & carcinogenesis ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background Thrombocytopenia is associated with increased mortality in the general population, but few data exist in patients with atrial fibrillation ( AF ) taking oral anticoagulants. We investigated factor determinants of thrombocytopenia in a large cohort of patients affected by AF and its association with total mortality. Methods and Results Multicenter prospective cohort study, including 5215 patients with AF from the START (Survey on Anticoagulated Patients Register) registry, 3877 (74.3%) and 1338 (25.7%) on vitamin K or non–vitamin K antagonist oral anticoagulants, respectively. Thrombocytopenia was defined by a platelet count 9 /L. Determinants of thrombocytopenia were investigated, and all‐cause mortality was the primary survival end point of the study. Thrombocytopenia was present in 592 patients (11.4%). At multivariable logistic regression analysis, chronic kidney disease (odds ratio [ OR], 1.257; P =0.030), active cancer ( OR, 2.065; P =0.001), liver cirrhosis ( OR, 7.635; P OR, 1.234; P =0.046) were positively associated with thrombocytopenia, whereas female sex ( OR, 0.387; P OR, 0.787; P =0.032) were negatively associated. During a median follow‐up of 19.2 months (9942 patient‐years), 391 deaths occurred (rate, 3.93%/year). Mortality rate increased from 3.8%/year to 9.9%/year in patients with normal platelet count and in those with moderate‐severe thrombocytopenia, respectively (log‐rank test, P =0.009). The association between moderate‐severe thrombocytopenia and mortality persisted after adjustment for CHA 2 DS 2 VAS c score (hazard ratio, 2.431; 95% CI, 1.254–4.713; P =0.009), but not in the fully adjusted multivariable Cox regression analysis model. Conclusions Thrombocytopenia is common in patients with AF . Despite an increased incidence of mortality, thrombocytopenia was not associated with mortality at multivariable analysis. Thrombocytopenia may reflect the presence of comorbidities associated with poor survival in AF .
- Published
- 2019
31. Consequences of warfarin suspension after major bleeding in very elderly patients with non valvular atrial fibrillation.
- Author
-
Zoppellaro G, Granziera S, Bertozzo G, Denas G, Marigo L, Petruzzellis F, Padayattil Jose S, Rossi K, Nante G, and Pengo V
- Subjects
- Aged, Aged, 80 and over, Anticoagulants adverse effects, Atrial Fibrillation complications, Atrial Fibrillation mortality, Cohort Studies, Female, Follow-Up Studies, Hemorrhage etiology, Hemorrhage mortality, Humans, Male, Stroke complications, Stroke mortality, Survival Analysis, Treatment Outcome, Warfarin adverse effects, Withholding Treatment, Anticoagulants therapeutic use, Atrial Fibrillation drug therapy, Hemorrhage prevention & control, Stroke drug therapy, Warfarin therapeutic use
- Published
- 2017
- Full Text
- View/download PDF
32. Anthropometric parameters and the incidence of atrial fibrillation in older people: the PRO.V.A study.
- Author
-
Trevisan C, Maggi S, Curreri C, Nante G, Noale M, De Rui M, Perissinotto E, Sartori L, Zambon S, Crepaldi G, Manzato E, and Sergi G
- Subjects
- Age Distribution, Age Factors, Aged, Aged, 80 and over, Atrial Fibrillation epidemiology, Atrial Fibrillation etiology, Female, Follow-Up Studies, Humans, Incidence, Italy epidemiology, Male, Obesity epidemiology, Obesity physiopathology, Prognosis, Retrospective Studies, Risk Factors, Sex Distribution, Time Factors, Waist Circumference, Anthropometry methods, Atrial Fibrillation physiopathology, Body Mass Index, Obesity complications, Population Surveillance
- Abstract
Background: Atrial fibrillation (AF) has been associated with body size and central obesity, but the impact of different anthropometric measures in this relationship has been inadequately investigated., Hypothesis: In this study, we examined the association between baseline anthropometric parameters with the incidence of AF in older people, hypothesizing that body size could impact the onset of AF more than fat distribution., Methods: Our study included 1764 participants with a mean age of 74.3 ± 6.9 years and no AF at baseline. Body mass index (BMI), body height, body surface area (BSA), waist and hip circumference, waist-to-stature ratio, waist-to-hip ratio, and mid-upper arm circumference (MUAC) were measured by trained physicians. AF was assessed after a 4.4-year follow-up., Results: There were 115 new cases of AF observed after the follow-up. Taking lower values of these measures for reference, the adjusted AF risk was 2.42 (95% confidence interval [CI]:1.88-3.12) for the highest stature quartile, 1.36 (95% CI:1.15-1.62) for BMI ≥30 kg/m
2 , 2.12 (95% CI:1.73-2.59) for the highest BSA quartile, 1.38 (95% CI: 1.21-1.56) for higher MUAC, and 1.39 (95% CI: 1.23-1.58, P < 0.0001) for higher hip circumference values. Central obesity did not seem to relevantly predict the onset of AF in our sample. Stature revealed the strongest impact on the onset of AF (5% higher risk of developing AF per 1 cm increase in height)., Conclusions: Body size, particularly tall stature and obesity, but not fat distribution, seems to be associated with the risk of AF in the elderly., (© 2017 Wiley Periodicals, Inc.)- Published
- 2017
- Full Text
- View/download PDF
33. Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism.
- Author
-
Pesavento R, Filippi L, Palla A, Visonà A, Bova C, Marzolo M, Porro F, Villalta S, Ciammaichella M, Bucherini E, Nante G, Battistelli S, Muiesan ML, Beltramello G, Prisco D, Casazza F, Ageno W, Palareti G, Quintavalla R, Monti S, Mumoli N, Zanatta N, Cappelli R, Cattaneo M, Moretti V, Corà F, Bazzan M, Ghirarduzzi A, Frigo AC, Miniati M, and Prandoni P
- Subjects
- Aged, Anticoagulants therapeutic use, Female, Follow-Up Studies, Humans, Hypertension, Pulmonary therapy, Incidence, Lung diagnostic imaging, Lung Diseases complications, Male, Middle Aged, Multivariate Analysis, Perfusion, Proportional Hazards Models, Prospective Studies, Pulmonary Embolism complications, Recurrence, Risk Factors, Secondary Prevention, Treatment Outcome, Venous Thromboembolism complications, Venous Thromboembolism drug therapy, Venous Thrombosis complications, Lung Diseases drug therapy, Pulmonary Embolism drug therapy
- Abstract
The impact of residual pulmonary obstruction on the outcome of patients with pulmonary embolism is uncertain.We recruited 647 consecutive symptomatic patients with a first episode of pulmonary embolism, with or without concomitant deep venous thrombosis. They received conventional anticoagulation, were assessed for residual pulmonary obstruction through perfusion lung scanning after 6 months and then were followed up for up to 3 years. Recurrent venous thromboembolism and chronic thromboembolic pulmonary hypertension were assessed according to widely accepted criteria.Residual pulmonary obstruction was detected in 324 patients (50.1%, 95% CI 46.2-54.0%). Patients with residual pulmonary obstruction were more likely to be older and to have an unprovoked episode. After a 3-year follow-up, recurrent venous thromboembolism and/or chronic thromboembolic pulmonary hypertension developed in 34 out of the 324 patients (10.5%) with residual pulmonary obstruction and in 15 out of the 323 patients (4.6%) without residual pulmonary obstruction, leading to an adjusted hazard ratio of 2.26 (95% CI 1.23-4.16).Residual pulmonary obstruction, as detected with perfusion lung scanning at 6 months after a first episode of pulmonary embolism, is an independent predictor of recurrent venous thromboembolism and/or chronic thromboembolic pulmonary hypertension., Competing Interests: Conflict of interest: None declared., (Copyright ©ERS 2017.)
- Published
- 2017
- Full Text
- View/download PDF
34. Short article: Relapsing Whipple's disease: a case report and literature review.
- Author
-
Ruggiero E, Zurlo A, Giantin V, Galeazzi F, Mescoli C, Nante G, Petruzzellis F, and Manzato E
- Subjects
- Aged, Anti-Bacterial Agents administration & dosage, Bacteriological Techniques, Biopsy, DNA, Bacterial genetics, Drug Administration Schedule, Duodenum pathology, Endoscopy, Digestive System, Humans, Male, Polymerase Chain Reaction, Predictive Value of Tests, Recurrence, Stomach microbiology, Stomach pathology, Treatment Outcome, Tropheryma drug effects, Tropheryma genetics, Whipple Disease diagnosis, Whipple Disease drug therapy, Duodenum microbiology, Tropheryma isolation & purification, Whipple Disease microbiology
- Abstract
Whipple's disease is a rare infection caused by Tropheryma whipplei, a Gram-negative Bacillus usually found in macrophages of the lamina propria of the small intestine. The typical clinical manifestations of classic Whipple's disease are diarrhea, weight loss, malabsorption, abdominal pain, and arthralgia. The disease's laboratory diagnosis is currently based on duodenal biopsy. Treatment generally includes primary therapy for 2 weeks with intravenous antibiotics capable of reaching high levels in the cerebrospinal fluid, such as ceftriaxone, usually followed by treatment with oral cotrimoxazole for 1 year. Early diagnosis should enable appropriate treatment and improves the prognosis, and prolonged antibiotic treatment often leads to complete remission. Our case report focuses on a 72-year-old man who had been passing watery stools for 1-2 months, accompanied by low-grade fever. He reported profound asthenia, a weight loss of about 3 kg, and loss of appetite. Thirty years earlier (in 1984), he had been working as a horse keeper at a University Department of Agricultural and Veterinary Studies, where he had contracted Whipple's disease. Laboratory tests and microbiological studies led to a diagnosis of recurrent Whipple's disease. Esophagogastroduodenoscopy was performed under deep sedation. Biopsy samples obtained from the stomach and duodenum were stained with hematoxylin and eosin, Giemsa, and periodic acid-Schiff to identify any accumulation of typical periodic acid-Schiff-positive macrophages in the lamina propria. A specific quantitative real-time PCR assay using specific oligonucleotide probes for targeting repeated sequences of Tropheryma whipplei was also performed to detect its DNA in the duodenum samples.
- Published
- 2016
- Full Text
- View/download PDF
35. A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation.
- Author
-
Pengo V, Zambon CF, Fogar P, Padoan A, Nante G, Pelloso M, Moz S, Frigo AC, Groppa F, Bozzato D, Tiso E, Gnatta E, Denas G, Padayattil Jose S, Padrini R, Basso D, and Plebani M
- Subjects
- Adult, Aged, Aged, 80 and over, Algorithms, Anticoagulants adverse effects, Anticoagulants therapeutic use, Cytochrome P-450 CYP2C9 metabolism, Cytochrome P-450 Enzyme System metabolism, Cytochrome P450 Family 4, Female, Humans, International Normalized Ratio methods, Male, Middle Aged, Pharmacogenetics methods, Polymorphism, Single Nucleotide, Stroke prevention & control, Treatment Outcome, Vitamin K Epoxide Reductases metabolism, Warfarin adverse effects, Warfarin therapeutic use, Anticoagulants administration & dosage, Atrial Fibrillation drug therapy, Drug Monitoring methods, Warfarin pharmacokinetics
- Abstract
Unlabelled: Genotype-guided warfarin dosing have been proposed to improve patient’s management. This study is aimed to determine whether a CYP2C9- VKORC1- CYP4F2-based pharmacogenetic algorithm is superior to a standard, clinically adopted, pharmacodynamic method. Two-hundred naïve patients with non-valvular atrial fibrillation were randomized to trial arms and 180 completed the study. No significant differences were found in the number of out-of-range INRs (INR<2.0 or >3.0) (p = 0.79) and in the mean percentage of time spent in the therapeutic range (TTR) after 19 days in the pharmacogenetic (51.9%) and in the control arm (53.2%, p = 0.71). The percentage of time spent at INR>4.0 was significantly lower in the pharmacogenetic (0.7%) than in the control arm (1.8%) (p = 0.02). Genotype-guided warfarin dosing is not superior in overall anticoagulation control when compared to accurate clinical standard of care., Trial Registration: ClinicalTrials.gov NCT01178034.
- Published
- 2015
- Full Text
- View/download PDF
36. To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort.
- Author
-
Granziera S, Bertozzo G, Pengo V, Marigo L, Denas G, Petruzzellis F, Rossi K, Infante T, Padayattil SJ, Perissinotto E, Manzato E, and Nante G
- Subjects
- Aged, Aged, 80 and over, Anticoagulants therapeutic use, Atrial Fibrillation epidemiology, Atrial Fibrillation psychology, Cohort Studies, Female, Humans, Male, Retrospective Studies, Risk Factors, Thromboembolism drug therapy, Thromboembolism etiology, Treatment Outcome, Thromboembolism prevention & control, Vitamin K antagonists & inhibitors, Warfarin therapeutic use
- Abstract
Despite the recommendations in the guidelines, physicians still underuse warfarin in very elderly patients with non-valvular atrial fibrillation (NVAF). The risks of stroke and major bleeding both increase with age, but it is still not clear whether the beneficial effects of vitamin K antagonists (VKA) in preventing stroke outweigh the related bleeding risks in fragile, very elderly patients. The bleeding rates reported in real-world observational studies differ considerably. The aim of this study was to retrospectively assess the incidence of major bleeding in VKA-naïve patients over 80 years old with NVAF at a large anticoagulation clinic. Significant predictors of major bleeding were also investigated. Sixty-five major bleeding events (3.4 per 100 patient-years) and 25 thromboembolic events (1.3 per 100 patient-years) were recorded in a sample of 798 patients with a median follow-up of 2.2 years. Patients over 85 years old had significantly more major bleeding events than the 80- to 84-year olds (4.7 vs. 2.6 per 100 patient-years, p 0.014). Spontaneous bleeding was also significantly more common (3.0 vs. 1.3 per 100 patient-years, p 0.008) in the very elderly group. Age and diabetes were the only independent risk factor for bleeding on multivariate Cox analysis (Age HR 1.80, 95% CI 1.10-2.93; diabetes HR 1.76, 95% CI 1.00-3.09). These data show a sharp increase in major bleeding episodes among the very elderly with atrial fibrillation. Further studies are warranted with a view to identifying patients at risk.
- Published
- 2015
- Full Text
- View/download PDF
37. Thromboembolic prevention in frail elderly patients with atrial fibrillation: a practical algorithm.
- Author
-
Granziera S, Cohen AT, Nante G, Manzato E, and Sergi G
- Subjects
- Aged, Aged, 80 and over, Algorithms, Anticoagulants administration & dosage, Atrial Fibrillation complications, Brain Ischemia etiology, Controlled Clinical Trials as Topic, Female, Humans, Male, Practice Guidelines as Topic, Thromboembolism etiology, Anti-Arrhythmia Agents administration & dosage, Atrial Fibrillation drug therapy, Brain Ischemia prevention & control, Frail Elderly statistics & numerical data, Thromboembolism prevention & control
- Abstract
Atrial fibrillation is a common condition in the elderly, and the incidence of thromboembolic events secondary to atrial fibrillation increases with age. Antithrombotic therapy effectively prevents stroke and systemic embolism but also exposes patients to the risk of bleeding. Because the risk of bleeding also increases with age, clinicians tend to withhold anticoagulation in the elderly. Anticoagulation is particularly complex in the frail elderly patient, who presents additional risk factors affecting both efficacy and safety of thromboembolic prevention. The main clinical trials rarely include frail elderly patients and, consequently, the guidelines do not provide guidance for their management. In the absence of clear indications for this class of patients, we identified some areas that should be taken into account both before starting and when discontinuing anticoagulation: comorbidities, polypharmacotherapy, adherence, cognitive impairment, mobility and monitoring barriers, nutritional status and swallowing disorders, risk of falls, and reduced life expectancy. We also suggest a multidimensional algorithm covering both a standard ischemic and bleeding risk assessment and an additional anticoagulation-focused frailty assessment. This is of particular relevance given the recent introduction of the oral direct inhibitors, as they are likely to widen the treatment options for the frail elderly. Depending on which aspect of frailty is present, anticoagulation can now be tailored accordingly., (Copyright © 2015 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
38. A new D-dimer cutoff in bedridden hospitalized elderly patients.
- Author
-
Granziera S, Rechichi A, De Rui M, De Carlo P, Bertozzo G, Marigo L, Nante G, and Manzato E
- Subjects
- Age Factors, Aged, 80 and over, Female, Hospitalization, Humans, Male, Venous Thrombosis diagnosis, Venous Thrombosis drug therapy, Aging blood, Fibrin Fibrinogen Degradation Products analysis, Venous Thrombosis blood
- Abstract
Asymptomatic deep vein thrombosis (DVT) and pulmonary embolism are leading causes of morbidity following the hospitalization of elderly people. The diagnosis of DVT is supported by the D-dimer laboratory assay. The concentration of D-dimer increases in patients with DVT, but may be high in other conditions too (i.e. cancer, infections and inflammation). Old age coincides with a physiological increase in D-dimer values, and that is why D-dimer assay in the elderly is characteristically highly sensitive but scarcely specific. The aim of our study was to explore the reliability of different D-dimer cutoffs for the diagnosis of asymptomatic DVT in a population of bedridden hospitalized elderly patients. We studied 199 patients who were a mean 86.3 ± 6.7 years old. All participants underwent lower limb Doppler ultrasound (DUS) and D-dimer venous blood sampling on admission. In our cohort, the usual cutoff proved highly sensitive (100%), but its specificity was very poor (20.1%). To find a higher cutoff that could improve the method's specificity, we analyzed our data using a receiver operating characteristic curve analysis. The resulting D-dimer cutoff of 492 μg/l enabled us to retain the same sensitivity while improving the test's specificity to 39.1%, with a consequent improvement in its positive predictive value and accuracy. In addition to improving the method's reliability, this result may be helpful in clinical practice, in both medical wards and nursing homes. By adopting a cutoff of 492 μg/l, clinicians could significantly increase the proportion of older patients in whom DVT can be safely ruled out, reducing referrals for DUS and administration of heparin, with consequent clinical, practical and economic advantages.
- Published
- 2013
- Full Text
- View/download PDF
39. Facioscapulohumeral muscular dystrophy and occurrence of heart arrhythmia.
- Author
-
Trevisan CP, Pastorello E, Armani M, Angelini C, Nante G, Tomelleri G, Tonin P, Mongini T, Palmucci L, Galluzzi G, Tupler RG, and Barchitta A
- Subjects
- Adolescent, Adult, Aged, Arrhythmias, Cardiac genetics, Echocardiography, Female, Humans, Male, Middle Aged, Molecular Diagnostic Techniques methods, Muscular Dystrophy, Facioscapulohumeral genetics, Neurologic Examination methods, Risk Factors, Severity of Illness Index, Arrhythmias, Cardiac complications, Arrhythmias, Cardiac epidemiology, Muscular Dystrophy, Facioscapulohumeral complications, Muscular Dystrophy, Facioscapulohumeral epidemiology
- Abstract
Background: Subjects with facioscapulohumeral muscular dystrophy (FSHD) do not generally suffer from significant cardiac symptoms. Although with heterogeneous results, studies reported to date indicate that heart alterations unrelated to cardiomyopathy are possible in FSHD., Patients and Methods: We describe the findings of a multicenter investigation aimed at detecting cardiac abnormalities in 83 FSHD patients, 44 males and 39 females with a mean age of 47 years. All patients underwent clinical heart examination, 12-lead electrocardiography and 24-hour Holter monitoring; echocardiography was also performed on most patients., Results: Among the 83 patients, 62 with no cardiovascular risk factors were identified. Ten of them manifested clinical or subclinical cardiac involvement: 5 reported symptoms represented mostly by frequent palpitations secondary to supraventricular arrhythmia and another 5 exhibited electrocardiographic signs of short runs of supraventricular paroxysmal tachycardia. In the absence of cardiovascular risk factors, we found symptoms or signs of heart involvement of mainly arrhythmic origin in 10 of our 83 FSHD patients (12%)., Conclusions: Considering our data and those available in the literature as a whole, arrhythmic alterations seem to be detected more frequently than expected in FSHD patients., (Copyright 2006 S. Karger AG, Basel.)
- Published
- 2006
- Full Text
- View/download PDF
40. [Asymptomatic deep vein thrombosis in the bedridden elderly. Role of D-dimer as screening test].
- Author
-
Busonera F, Verlato F, Nante G, Buttarello M, De Biasio V, Tiozzo F, Albanese P, Enzi G, and Andreozzi GM
- Subjects
- Age Factors, Aged, Humans, Prospective Studies, Sensitivity and Specificity, Fibrin Fibrinogen Degradation Products analysis, Immobilization, Venous Thrombosis blood, Venous Thrombosis diagnosis
- Published
- 1999
41. [Tuberculous pancreatic abscess in a case of miliary lung tuberculosis].
- Author
-
Meneghello A, Mantovan M, and Nante G
- Subjects
- Aged, Female, Humans, Abscess complications, Pancreatic Diseases complications, Tuberculosis, Endocrine complications, Tuberculosis, Miliary complications
- Published
- 1997
42. [Tolerability of nimesulide in the aged].
- Author
-
Nante G, Dal Prà ML, Mosca M, and De Candia O
- Subjects
- Age Factors, Aged, Aged, 80 and over, Drug Evaluation, Drug Tolerance, Humans, Middle Aged, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Arthritis drug therapy, Osteoporosis drug therapy, Sulfonamides therapeutic use
- Published
- 1988
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.